We are live on
!
Find out more
TCP
Tyndall Capital Partners Portfolio holdings
AUM
$452K
1-Year Est. Return
26.52%
This Fund
S&P 500
This Quarter
Est. Return
-41.55%
1 Year Est. Return
+26.52%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.84M
AUM Growth
–
Cap. Flow
+$2.31M
Cap. Flow
% of AUM
125.41%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
2
New
2
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Traws Pharma
TRAW
|
+$1.9M |
| 2 |
ONTXW
Onconova Therapeutics, Inc. Warrants
ONTXW
|
+$413K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.8% |
| 2 | Miscellaneous | 21.2% |
Similar funds
CCM
HIP
BPWM
NP
CP
AI
CAWM
ADIM
Tyndall Capital Partners's Q3 2016 Portfolio in Review
Q3 2016 is the first quarter with a 13F filing on record for Tyndall Capital Partners, which disclosed 2 positions worth $1.84M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Traws Pharma: 93 shares worth $1.45M.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, followed by Miscellaneous.
- Tyndall Capital Partners's largest Q3 2016 buy was Traws Pharma: 93 shares worth $1.45M.
- Tyndall Capital Partners's ten largest holdings make up 100% of its $1.84M portfolio in Q3 2016.
- Tyndall Capital Partners disclosed 2 positions in Q3 2016, its first 13F filing on record.
Based on Tyndall Capital Partners's 13F filing for Q3 2016, filed 14 Nov 2016.